Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Proposals for population screening for genetic diseases require careful scrutiny by decision makers because of the potential for harms and the need to demonstrate benefits commensurate with the opportunity cost of resources expended. Methods: We review current evidence-based processes used in the United States, the United Kingdom, and the Netherlands to assess genetic screening programs, including newborn screening programs, carrier screening, and organized cascade testing of relatives of patients with genetic syndromes. In particular, we address critical evidentiary, economic, and ethical issues that arise in the appraisal of screening tests offered to the population. Specific case studies include newborn screening for congenital adrenal hyperplasia and cystic fibrosis and adult screening for hereditary hemochromatosis. Results: Organizations and countries often reach different conclusions about the suitability of screening tests for implementation on a population basis. Deciding when and how to introduce pilot screening programs is challenging. In certain cases, e.g., hereditary hemochromatosis, a consensus does not support general screening although cascade screening may be cost-effective. Conclusion: Genetic screening policies have often been determined by technological capability, advocacy, and medical opinion rather than through a rigorous evidence-based review process. Decision making should take into account principles of ethics and opportunity costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Newborn screening: toward a uniform screening panel and system—executive summary
Watson, M. S., Mann, M. Y., Lloyd-Puryear, M. A., Rinaldo, P., Howell, R. R., & American College of Medical Genetics Newborn Screening Expert Group (2006) · Pediatrics · doi:10.1542/peds.2005-2633i · Cited by 494
Comprehensive cost-utility analysis of newborn screening strategies
Carroll, A. E., & Downs, S. M. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2633h · Cited by 165
How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?
Grosse, S. D., & Van Vliet, G. (2007) · Hormone Research in Paediatrics · doi:10.1159/000098400 · Cited by 102
Self-citationThe cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study
Rogowski, W. H. (2009) · Medical Decision Making · doi:10.1177/0272989x08327112 · Cited by 42
Self-citationThe cost effectiveness of screening newborns for congenital adrenal hyperplasia
Yoo, B. K., & Grosse, S. D. (2009) · Public Health Genomics · doi:10.1159/000156115 · Cited by 37 · cited 3×
“states that have set cost-benefit or cost-effectiveness as a criterion have made it sufficiently loose for it to not be restrictive in practice [59] . In the United Kingdom, although costeffectiveness is a stated criterion for the National Screening Committee [ 15 ] , it does not appear to have played a determining ro…”
BackgroundMethodInfluentialSelf-citationStrnadová, K. A., Votava, F., Lebl, J., Mühl, A., Item, C., Bodamer, O. A., Torresani, T., Bouška, I., Waldhauser, F., & Sperl, W. (2006) · European Journal of Pediatrics · doi:10.1007/s00431-006-0154-8 · Cited by 30
Cited by
Kapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980
Klinefelter Syndrome: Integrating Genetics, Neuropsychology, and Endocrinology
Gravholt, C. H., Chang, S., Wallentin, M., Fedder, J., Moore, P., & Skakkebæk, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00212 · Cited by 328
Recommendations for returning genomic incidental findings? We need to talk!
Burke, W., Matheny Antommaria, A. H., Bennett, R., Botkin, J., Clayton, E. W., Henderson, G. E., Holm, I. A., Jarvik, G. P., Khoury, M. J., Knoppers, B. M., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.113 · Cited by 293
Self-citationThe changing face of Turner syndrome
Gravholt, C. H., Viuff, M., Just, J., Sandahl, K., Brun, S., van der Velden, J., Andersen, N. H., & Skakkebaek, A. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac016 · Cited by 149
Viuff, M. H., Stochholm, K., Uldbjerg, N., Nielsen, B. B., the Danish Fetal Medicine Study Group, & Gravholt, C. H. (2015) · Human Reproduction · doi:10.1093/humrep/dev192 · Cited by 78
Metadata
- Authors
- Grosse, S. D., Rogowski, W. H., Ross, L. F., Cornel, M. C., Dondorp, W. J., & Khoury, M. J.
- Venue
- Public Health Genomics
- Publisher
- S. Karger AG
- Published
- 2009-06-29
- Volume
- 13
- Issue
- 2
- Pages
- 106-115
- ISSN
- 1422-2795 (ISSN-L)
- 1662-4246
- 1662-8063
- OpenAlex
- W2074227154
- Cited by
- 138
- References
- 8
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.